Regenesance, developing novel treatments
for immune mediated and neurodegenerative disorders
First Therapeutic Product Focus
Regenesance is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway.
Regenesance is focused on developing treatments for the orphan drug indications...
Regenesance has developed the monoclonal antibody Regenemab™ for the treatment of neurodegenerative and immune mediated disorders, first target indication is PNH.
Regenesance presenting on BioCapital Europe. March 26, 2015.
EPIC Biotech, October 2015
Regenesance presenting on EPIC Biotech. October 8, 2015.
Regenesance antibody fully characterized and ready for production.